Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SKŘIČKOVÁ Jana BABIČKOVÁ Lenka KAPLANOVÁ Jana KUBOVÁ Olga PALKOVA Ivana TOMÍŠKOVÁ Marcela

Year of publication 2003
Type Article in Proceedings
Conference Woorkbook of Iressa Clinical Experience Meeting
MU Faculty or unit

Faculty of Medicine

Citation
Field Pneumology
Keywords non-small-cell lung cancer; gefitinib treatment; survival rate
Description Forty-five patients with non-small-cell lung cancer underwent treatment with gefitinib; 51% of them had prior radiotherapy. Treatment duration was 1 to 14 months (median, 3 months). Diseased progressed in 18 patients within 3 months, but stabilised in 27 patients for longer than 3 months. Disease-related symptoms were generally milder after gefitinib treatment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info